PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Steven Brem, MD - Rethinking Glioblastoma Care in an Evolving Therapeutic Landscape: Expert Perspectives on Modern Modalities, Novel Agents, and Combinations
Go online to PeerView.com/CBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As new therapeutic strategies are explored and validated, oncologists have more effective treatments to offer their patients with glioblastoma, the most common and lethal brain tumor in adults. Tumor treating fields (TTFields), a novel modality, has been an important step forward in improving outcomes in glioblastoma and has increased the armamentarium beyond surgical resection, radiation therapy, and chemotherapy. Moreover, targeted therapies continue to demonstrate promising results. Join PeerView and the American Brain Tumor Association to learn about the latest evidence on TTFields and other treatment strategies, including targeted therapies, such as antiangiogenic antibodies and multikinase and TRK inhibitors, that are being explored in glioblastoma. In this CME-certified activity, a panel of experts in neuro-oncology will provide insights on the future of glioblastoma management, strategies for integrating therapeutic advances into the clinic, and approaches to personalizing care, including the considerations of clinical trial enrollment, for patients with glioblastoma. Upon completion of this activity, participants should be better able to: Evaluate the rationale and pivotal clinical evidence on guideline-recommended treatment strategies, such as tumor treating fields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent glioblastoma, Review the latest safety and efficacy evidence and ongoing clinical trials investigating novel agents, including immune checkpoint, multikinase, gene fusion, proteasome, PARP, EGFR, and nuclear export inhibitors, for the therapeutic management of glioblastoma, Develop safe and effective personalized treatment plans, including consideration of clinical trial enrollment, for patients with newly diagnosed and recurrent glioblastoma.